Ampio Pharmaceuticals, Inc.
Lucentis from Roche (NASDAQOTH: RHHBY) and Novartis (NYSE: NVS), and Eylea from Regeneron (NASDAQ: REGN) were recently approved by the FDA and combined are already producing revenues of close to $2.5 billion. The shares of Roche and Novartis may be down a bit from their recent highs one month ago, but Regeneron continues to streak to new highs and give shareholders a spectacular ride.
Lucentis and Eylea are both more »
Optina in Oral Form Likely to Become Preferred Treatment For Diabetic Macular Edema Over Monthly Injection Into the Eye
Diabetic Macular Edema "DME" threatens the eyesight of millions of patients every year and the number is growing rapidly driven by soaring rates of diabetes. In DME, the blood vessels in the retina leak blood and fluids into delicate retinal tissue where the sight receptors reside causing swelling of the retina more »
What is novel about the company’s strategy is that their product pipeline is largely based on developing new uses for previously approved drugs and new molecular entities ("NMEs").